Galmed Pharmaceuticals reported net losses of $2.723 million for the three months and $4.633 million for the six months ended June 30, 2026, with basic and diluted loss per share of $2.81 and $5.21. The results matter to investors because higher Research and Development spending accompanied operating losses.

Key Highlights

  • Total Assets stood at $18.283 million as of June 30, 2026.
  • Current assets totaled $11.713 million, while non-current assets reached $6.570 million.
  • Galmed had 112,500,000 ordinary shares authorized and 1,001,394 issued and outstanding at June 30, 2026.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) reported net losses of $2.723 million for the three months and $4.633 million for the six months ended June 30, 2026. Basic and diluted net loss per share was $2.81 for the quarter and $5.21 for the six-month period. Comprehensive loss was $2.671 million and $4.661 million for the respective periods. Research and development expenses increased during both reporting periods, while the company recorded operating losses and net losses.

R&D Spending Moves Higher

Net loss reached $2.723 million for the quarter and $4.633 million for the six months. Financial results also included net financial income, financial expenses related to SEPA and comprehensive loss.

Assets Total $18.283 Million

Total assets were $18.283 million as of June 30, 2026. Current assets accounted for $11.713 million, including cash and cash equivalents of $2.885 million, restricted cash of $159,000, marketable Debt securities of $5.881 million, short-term deposits of $2.465 million and other receivables of $323,000. Non-current assets totaled $6.570 million. That balance included property and equipment of $48,000, other intangible assets of $4.642 million, Goodwill of $1.764 million and an operating Lease right-of-use asset of $116,000. Current liabilities were $2.814 million, consisting of trade payables of $1.897 million, other payables of $834,000 and operating lease liabilities of $83,000. Non-current liabilities totaled $2.731 million, including contingent consideration of $1.617 million, a deferred tax Liability of $1.068 million and operating lease liabilities of $46,000.

Ordinary Share Structure

Galmed’s ordinary shares have a Par Value of NIS 14.4 per share. The company was authorized to issue 112,500,000 ordinary shares, with 1,001,394 issued and outstanding as of June 30, 2026. Stockholders’ Equity included ordinary share capital, additional paid-in capital, accumulated other comprehensive loss and accumulated deficit. The company reported total stockholders’ equity of $12.738 million at the end of the period.